Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2022

17.08.2022 | short review

CAR T cells in multiple myeloma: Where we stand and where we might be going

verfasst von: PD Dr. Niklas Zojer, Dr. Martin Schreder, Univ.-Prof. Dr. Heinz Ludwig

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

In this review we highlight the current developments in Chimeric antigen receptor (CAR) T cell therapy for myeloma. Two advanced products (idecabtagene vicleucel and ciltacabtagene autoleucel) targeting B‑cell maturation antigen have already been approved by the US Food and Drug Administration (FDA). In heavily pretreated myeloma patients, response rates between 82 and 98% and a median progression-free survival between 12 and > 24 months have been achieved. Currently these two products are being investigated in earlier lines of therapy. Beside BCMA, other targets have been selected for CAR T cell therapy in myeloma, with advanced constructs targeting two antigens. We highlight current strategies to improve CAR T cell effectiveness and safety and give a personal outlook where cellular immunotherapy in myeloma might be heading.
Literatur
1.
Zurück zum Zitat Teoh PJ, Chng WJ. CAR T‑cell therapy in multiple myeloma: more room for improvement. Blood Cancer J. 2021;11(4):84. CrossRef Teoh PJ, Chng WJ. CAR T‑cell therapy in multiple myeloma: more room for improvement. Blood Cancer J. 2021;11(4):84. CrossRef
2.
Zurück zum Zitat Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–16. CrossRef Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–16. CrossRef
3.
Zurück zum Zitat Martin T, Usmani SZ, Berdeja JG, et al. Updated results from CARTITUDE-1: phase 1b/2study of ciltacabtagene autoleucel, a B-cell maturation antigen—directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma. Abstract. 63rd ASH Annual Meeting & Exposition. Vol. 549. 2021. Martin T, Usmani SZ, Berdeja JG, et al. Updated results from CARTITUDE-1: phase 1b/2study of ciltacabtagene autoleucel, a B-cell maturation antigen—directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma. Abstract. 63rd ASH Annual Meeting & Exposition. Vol. 549. 2021.
4.
Zurück zum Zitat Mateos MV, Weisel K, Martin T, et al. Ciltacabtagene autoleucel for triple-class exposed multiple myeloma: adjusted comparisons of CARTITUDE-1 patient outcomes versus therapies from real-world clinical practice from the LocoMMotion prospective study. Abstract. 63rd ASH Annual Meeting & Exposition. Vol. 550. 2021. Mateos MV, Weisel K, Martin T, et al. Ciltacabtagene autoleucel for triple-class exposed multiple myeloma: adjusted comparisons of CARTITUDE-1 patient outcomes versus therapies from real-world clinical practice from the LocoMMotion prospective study. Abstract. 63rd ASH Annual Meeting & Exposition. Vol. 550. 2021.
5.
Zurück zum Zitat Van de Donk NW, Themeli M, Usmani SZ. Determinants of response and mechanisms of resistance of CAR T‑cell therapy in multiple myeloma. Blood Cancer Discov. 2021;2(4):302–18. CrossRef Van de Donk NW, Themeli M, Usmani SZ. Determinants of response and mechanisms of resistance of CAR T‑cell therapy in multiple myeloma. Blood Cancer Discov. 2021;2(4):302–18. CrossRef
7.
Zurück zum Zitat Atamaniuk J, Gleiss A, Porpaczy E, et al. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Invest. 2012;42(9):953–60. CrossRef Atamaniuk J, Gleiss A, Porpaczy E, et al. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Invest. 2012;42(9):953–60. CrossRef
8.
Zurück zum Zitat Mailankody S, Diamonte C, Fitzgerald L, et al. Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma. Abstract. 63rd ASH Annual Meeting & Exposition. Vol. 827. 2021. Mailankody S, Diamonte C, Fitzgerald L, et al. Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma. Abstract. 63rd ASH Annual Meeting & Exposition. Vol. 827. 2021.
9.
Zurück zum Zitat Zah E, Nam E, Bhuvan V, et al. Systematically optimized BCMA/CS1 bispecific CAR‑T cells robustly control heterogeneous multiple myeloma. Nat Commun. 2020;11(1):2283. CrossRef Zah E, Nam E, Bhuvan V, et al. Systematically optimized BCMA/CS1 bispecific CAR‑T cells robustly control heterogeneous multiple myeloma. Nat Commun. 2020;11(1):2283. CrossRef
10.
Zurück zum Zitat Mei H, Li C, Jiang H, et al. A bispecific CAR‑T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol. 2021;14(1):161. CrossRef Mei H, Li C, Jiang H, et al. A bispecific CAR‑T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol. 2021;14(1):161. CrossRef
12.
Zurück zum Zitat Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T‑cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–24. CrossRef Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T‑cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–24. CrossRef
13.
Zurück zum Zitat Mailankody S, Jakubowiak AJ, Htut M, et al. Orvacabtagene autoleucel (orva-cel), a B‑cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011). J Clin Oncol. 2020;38(15_suppl):8504. CrossRef Mailankody S, Jakubowiak AJ, Htut M, et al. Orvacabtagene autoleucel (orva-cel), a B‑cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011). J Clin Oncol. 2020;38(15_suppl):8504. CrossRef
14.
Zurück zum Zitat Raje NS, Shah N, Jagannath S, et al. Updated clinical and correlative results from the phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma. Abstract. 63rd ASH Annual Meeting & Exposition. Vol. 548. 2021. Raje NS, Shah N, Jagannath S, et al. Updated clinical and correlative results from the phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma. Abstract. 63rd ASH Annual Meeting & Exposition. Vol. 548. 2021.
15.
Zurück zum Zitat Mailankody S, Liedtke M, Sidana S, et al. Universal updated phase 1 data validates the feasibility of allogeneic anti-BCMA ALLO-715 therapy for relapsed/refractory multiple myeloma. Abstract. 63rd ASH Annual Meeting & Exposition. Vol. 651. 2021. Mailankody S, Liedtke M, Sidana S, et al. Universal updated phase 1 data validates the feasibility of allogeneic anti-BCMA ALLO-715 therapy for relapsed/refractory multiple myeloma. Abstract. 63rd ASH Annual Meeting & Exposition. Vol. 651. 2021.
16.
Zurück zum Zitat Pont MJ, Hill T, O’Cole G, et al. γ‑Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019;134(19):1585–97. CrossRef Pont MJ, Hill T, O’Cole G, et al. γ‑Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019;134(19):1585–97. CrossRef
17.
Zurück zum Zitat Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T‑cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726–37. CrossRef Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T‑cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726–37. CrossRef
18.
Zurück zum Zitat Mestermann K, Giavridis T, Weber J, et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci Transl Med. 2019;11(499):eaau5907. CrossRef Mestermann K, Giavridis T, Weber J, et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci Transl Med. 2019;11(499):eaau5907. CrossRef
19.
Zurück zum Zitat Van Oekelen O, Aleman A, Upadhyaya B, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR‑T cell therapy. Nat Med. 2021;27(12):2099–103. CrossRef Van Oekelen O, Aleman A, Upadhyaya B, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR‑T cell therapy. Nat Med. 2021;27(12):2099–103. CrossRef
20.
Zurück zum Zitat Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147–67. CrossRef Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147–67. CrossRef
21.
Zurück zum Zitat Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5(215):215ra172. CrossRef Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5(215):215ra172. CrossRef
24.
Zurück zum Zitat Carbone E, Neri P, Mesuraca M, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood. 2005;105(1):251–8. CrossRef Carbone E, Neri P, Mesuraca M, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood. 2005;105(1):251–8. CrossRef
25.
Zurück zum Zitat Chu J, Deng Y, Benson DM, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014;28(4):917–27. CrossRef Chu J, Deng Y, Benson DM, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014;28(4):917–27. CrossRef
26.
Zurück zum Zitat Jiang H, Zhang W, Shang P, et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol. 2014;8(2):297–310. CrossRef Jiang H, Zhang W, Shang P, et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol. 2014;8(2):297–310. CrossRef
27.
Zurück zum Zitat Poels R, Drent E, Lameris R, et al. Preclinical evaluation of invariant natural killer T cells modified with CD38 or BCMA chimeric antigen receptors for multiple myeloma. Int J Mol Sci. 2021;22(3):1096. CrossRef Poels R, Drent E, Lameris R, et al. Preclinical evaluation of invariant natural killer T cells modified with CD38 or BCMA chimeric antigen receptors for multiple myeloma. Int J Mol Sci. 2021;22(3):1096. CrossRef
28.
Zurück zum Zitat Leivas A, Valeri A, Codoba L, et al. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J. 2021;11(8):146. CrossRef Leivas A, Valeri A, Codoba L, et al. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J. 2021;11(8):146. CrossRef
Metadaten
Titel
CAR T cells in multiple myeloma: Where we stand and where we might be going
verfasst von
PD Dr. Niklas Zojer
Dr. Martin Schreder
Univ.-Prof. Dr. Heinz Ludwig
Publikationsdatum
17.08.2022
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00825-6